Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Traiettorie di recupero longitudinali dopo una sindrome da distress respiratorio acuto, una nuova comprensione (TENACITY)

2 novembre 2026 aggiornato da: Jessica González Gutiérrez MD, PhD, Institut de Recerca Biomèdica de Lleida

Traiettorie di recupero longitudinali dopo una sindrome da distress respiratorio acuto, una nuova comprensione. Lo Studio TENACIA

COVID-19 resulted in the largest cohort of critical illness survivors in history, heightened awareness of the importance of the respiratory sequelae after an acute distress respiratory syndrome (ADRS). Despite the advancement of acute-phase ARDS management, it is unknown whether there are differences in the longitudinal recovery trajectories between patients with post-ARDS due to COVID-19 and due to other causes. The main objective of the study is to identify risk factors of pulmonary sequela (lung diffusing capacity) at long-term follow-up in survivors of ARDS. The investigators are also interested in describing the long-term longitudinal recovery trajectories at a multi-dimensional level (symptoms, quality of life, neurocognitive, other lung function parameters, exercise capacity, chest imaging and molecular profiles) of ARDS survivors, and compared between ARDS caused by COVID-19. The ultimate goal is to understand the pathobiological mechanisms associated with a severe lung injury at the long term, allowing the introduction of clinical guidelines for the management of post-ARDS patients and the assignment of personalized interventions.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Descrizione dettagliata

The coronavirus disease 2019 (COVID-19) resulted in the largest cohort of critical illness survivors in history, heightened awareness of the importance of the multi-dimensional sequelae after an acute distress respiratory syndrome (ADRS). With the advancement of acute-phase ARDS management, it is unknown whether there are differences in longitudinal recovery trajectories in terms of lung function, symptoms, quality of life, neurocognitive disorders, exercise capacity, chest imaging, and even at molecular basis between patients with post-ARDS due to COVID-19 and due to other causes. This project will continue to generate information about non-COVID-19 post-ARDS based on the experience in our post-COVID consultation that began in May 2020.

The main objective of the study is to identify risk factors of pulmonary sequela in terms of DLCO at long-term follow-up in survivors of ARDS. The investigators are also interested in describing the long-term longitudinal recovery trajectories at a multidimensional level (symptoms, quality of life, neurocognitive, other lung function parameters, exercise capacity, chest imaging and molecular profiles) of ARDS survivors. Furthermore, risk factors as well as recovery trajectories will be compared between ARDS caused by COVID-19 and non-COVID-19. The ultimate goal is to understand the pathobiological mechanisms associated with a severe lung injury at the long term (one year after hospital discharge), in order to provide novel therapeutic targets to develop future intervention studies.

For doing so, adult ARDS survivors of any origin (different than COVID-19) (n=246) referred to the post-CRITICAL consultation at the University Hospitals of Arnau de Vilanova and Santa Maria (Lleida), University Hospital Joan XXIII (Tarragona) and Verge de la Cinta (Tortosa) will be included in this multicentric, prospective, longitudinal and observational study. Previous standardized protocol will be followed at 3, 6 and 12 months after hospital discharge with a complete evaluation of symptoms, neurocognitive, memory problems and quality of life. Lung function, exercise test, chest CT and molecular analysis will be performed at each time point. The prognostic factors and the longitudinal recovery trajectories of ARDS survivors will be assessed using latent class mixed and machine learning artificial models.

The specific objectives to achieve the general objective are the following:

Objective 1: To identify risk factors of lung function sequelae (spirometry, total lung volumes and lung diffusing capacity) in non-COVID-19 ARDS survivors.
Objective 2: To identify risk factors of structural pulmonary sequelae (chest CT findings) in non-COVID-19 ARDS survivors.
Objective 3: To identify risk factors of symptoms, neurocognitive disorders (BC-CCI, MOCA) and quality of life (SF-12) in non-COVID-19 ARDS survivors.
Objective 4: To develop a clinical scoring tool to predict pulmonary sequelae at short- and long-term follow-up.
Objective 5: To compare risk factors and recovery trajectories with COVID-19 ARDS survivors using data previously collected.
Objective 6: To use artificial intelligence to identify multidimensional phenotypes associated with recovery trajectories.
Objective 7: To design a cost-effective follow-up plan after hospital discharge in ARDS patients based on hospital risk factors.
Objective 8: To identify molecular profiles according to recovery trajectories in non-COVID-19 ARDS.

Tipo di studio

Osservativo

Iscrizione (Stimato)

246

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

Spagna
- Lleida
  - Lleida, Lleida, Spagna, 25198
    - Hospital Universitari Arnau de Vilanova
- Tarragona
  - Tarragona, Tarragona, Spagna, 43005
    - Hospital Universitari Joan XXIII
  - Tortosa, Tarragona, Spagna, 43500
    - Hospital de Tortosa Verge de la Cinta

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Critical patients admited to the intensive care unit of the 3 participant hospitals whot meet the eligibility criteria.

Descrizione

Inclusion Criteria:

Male and female patients aged ≥18 years
Admission to the ICU
Diagnosis of severe pneumonia and/or diagnosis of acute respiratory distress syndrome (ARDS) based on the 2023 definition due to any origin (infectious and non-infectious)

Exclusion Criteria:

Life expectancy less than a year
Transfer to another hospital during hospitalization or follow-up
Stay in palliative care
Severe mental disability that makes it impossible to carry out pulmonary function tests during follow-up

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Modelli osservazionali: COHORT
Prospettive temporali: PROSPECTIVE

Numero di gruppi/coorti

Coorti e interventi

Gruppo / Coorte
post-ICU with ARDS Patients admitted to the ICU who have developed Acute Respiratory Distress Syndrome (ARDS), as defined according the new 2023 guidelines (Matthay et.al, 2023)
post-ICU without ARDS Patients admitted to the ICU who have suffered a severe pneumonia, needing advanced respiratory support, but without developing ARDS according to the new 2023 guidelines.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato	Misura Descrizione	Lasso di tempo
Changes in lung diffusing capacity Lasso di tempo: 3, 6 and 12 months	Changes in the results of lung diffusing capacity (DLCO) in terms of mL/mmHg/MI	3, 6 and 12 months
Changes in lung diffusing capacity Lasso di tempo: 3, 6 and 12 months	Changes in the results of lung diffusing capacity (DLCO) in terms of percentage (%)	3, 6 and 12 months
Changes in lung volumes Lasso di tempo: 3, 6 and 12 months	Changes in the results of lung capacity or total lung capacity (TLC) in terms of Liters (L)	3, 6 and 12 months
Changes in lung volumes Lasso di tempo: 3, 6 and 12 months	Changes in the results of lung capacity or total lung capacity (TLC) in terms of percentage (%)	3, 6 and 12 months
Changes in chest CT findings Lasso di tempo: 3, 6 and 12 months	Identification of structural pulmonary sequelae in terms of chest CT findings	3, 6 and 12 months

Misure di risultato secondarie

Misura del risultato	Misura Descrizione	Lasso di tempo
Changes in the perceived cognitive difficulties Lasso di tempo: 3, 6 and 12 months	Changes in the results of the British Columbia Cognitive Complaints Inventory (BC-CCI) test. The scale consists of 6 items assessing perceived problems with concentration, memory, expressing thoughts, word finding, slow thinking, and difficulty solving problems in the past 7 days. Scores on each item (ranging from 0, not at all, to 3, very much) are summed to yield a total score ranging from 0 to 18; higher scores indicate greater severity of cognitive complaints.	3, 6 and 12 months
Changes in the cognitive function Lasso di tempo: 3, 6 and 12 months	Changes in the results of Montreal Cognitive Assessment (MoCA) test. The MoCA test examines seven domains of cognitive function with a total of 11 different exercises and tasks. The total score ranges from 0 to 30, lower scores indicate greater severity of cognitive impairment.	3, 6 and 12 months
Changes in the fatigue status Lasso di tempo: 3, 6 and 12 months	Changes in the results of Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale (Version 4) This scale is a short test of 13-item that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The total score range is 0-52, being the higher the score, the better the quality of life and less perception of fatigue.	3, 6 and 12 months
Changes in the levels of anxiety Lasso di tempo: 3, 6 and 12 months	Changes in the results of Hospital Anxiety and Depression Scale (HAD) The scale determines the levels of anxiety and depression that a person is experiencing. It is a 14 item scale (7 of the items relate to anxiety and 7 relate to depression). Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. Lower scores indicate less anxiety or depression.	3, 6 and 12 months
Changes in independence to carry out daily activities Lasso di tempo: 3, 6 and 12 months	Changes in the results of Barthel test. Barthel Index (BI) measures the extent to which somebody can function independently and has mobility in their activities of daily living. The Index yields a total score out of 100 - the higher the score, the greater the degree of functional independence. This score is calculated by simply totaling the individual item scores.	3, 6 and 12 months
Changes in the perception of life quality Lasso di tempo: 3, 6 and 12 months	Changes in the results of 12-Item Short Form Survey (SF-12) test. The SF-12 is a self-reported outcome measure composed by 12 items which examine eight dimensions of physical and mental health. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.	3, 6 and 12 months
Validation of a clinical scoring tool Lasso di tempo: 3, 6 and 12 months	Validation of a clinical scoring tool to predict pulmonary sequelae at short- and long-term follow-up.	3, 6 and 12 months
Cost-effectiveness of a follow-up plan Lasso di tempo: 3, 6 and 12 months	Only direct costs will be considered. Analysis will include an estimation of quality-adjusted life-years (QALYs) gained	3, 6 and 12 months
Identification of molecular profiles Lasso di tempo: 3, 6 and 12 months	Classification of the population in different molecular profiles according to their recovery trajectories	3, 6 and 12 months
Multidimensional phenotypes Lasso di tempo: 3, 6 and 12 months	multidimensional phenotypes associated with recovery trajectories defined with artificial intelligence	3, 6 and 12 months
Recovery trajectories of lung diffusing capacity Lasso di tempo: 3, 6 and 12 months	Comparison of risk factors and recovery trajectories in terms of lung diffusing capacity (DLCO) with COVID-19 ARDS survivors using data previously collected.	3, 6 and 12 months
Recovery trajectories of total lung capacity Lasso di tempo: 3, 6 and 12 months	Comparison of risk factors and recovery trajectories in terms of total lung capacity (TLC) with COVID-19 ARDS survivors using data previously collected.	3, 6 and 12 months
Recovery trajectories of perception of life quality Lasso di tempo: 3, 6 and 12 months	Comparison of risk factors and recovery trajectories in terms of perception of life quality (SF12 test) with COVID-19 ARDS survivors using data previously collected.	3, 6 and 12 months
Recovery trajectories of perception of fatigue Lasso di tempo: 3, 6 and 12 months	Comparison of risk factors and recovery trajectories in terms of perception of fatigue (FACIT-4 test) with COVID-19 ARDS survivors using data previously collected.	3, 6 and 12 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Institut de Recerca Biomèdica de Lleida

Collaboratori

Instituto de Salud Carlos III

Investigatori

Investigatore principale: Jessica González Gutiérrez, MD, PhD, Institut de Recerca Biomèdica de Lleida

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

29 giugno 2023

Completamento primario (Stimato)

1 luglio 2027

Completamento dello studio (Stimato)

30 giugno 2028

Date di iscrizione allo studio

Primo inviato

4 settembre 2023

Primo inviato che soddisfa i criteri di controllo qualità

11 ottobre 2023

Primo Inserito (Effettivo)

16 ottobre 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

4 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

PI23/01381

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .